Click here to go to the previous page
Noninterventional Minimal Risk Research: A 360° Perspective
Program Code:
256
Date:
Tuesday, June 26, 2012
Time:
1:30 PM to 3:00 PM
EST
CHAIR
:
Ms. Coleman is the Director of Regulatory Affairs/General Counsel at Quorum Review IRB. Prior to Quorum, she was an attorney at Bennett Bigelow & Leedom where her practice focused on health law, Medicare/Medicaid reimbursement, and employment law for healthcare related organizations.
|
PRESENTER
(S):
Kathleen Mandziuk, PRA
Lindsay Crampton is a Project Manager in Global Late Stage Research at PPD. She has more than 8 years experience in the pharmaceutical industry, all directly involved in REMS programs and pregnancy observational studies.
|
Ms. Meeker-O’Connell joined CDER’s Office of Scientific Investigations in March 2010. Prior to FDA, Ann spent 10 years in clinical compliance roles in industry and academia. Ann is actively involved in initiatives to develop risk-based approaches to clinical trial design, conduct, and oversight.
|
Ms. Coleman is the Director of Regulatory Affairs/General Counsel at Quorum Review IRB. Prior to Quorum, she was an attorney at Bennett Bigelow & Leedom where her practice focused on health law, Medicare/Medicaid reimbursement, and employment law for healthcare related organizations.
|
Description
In this interactive session, experts will explore the various types of noninterventional minimal risk studies (including postapproval noninterventional studies, registries, safety-surveillance, and REMS) and their design to ensure compliance with regulatory requirements. The session will also explore the IRB, industry, and site perspective including the value of noninterventional minimal risk studies and models for streamlining the IRB review process.
Learning Objectives:
Describe the agency, IRB, industry, and site perspective regarding studies that qualify as non-interventional minimal risk research
Discuss the various types of noninterventional minimal risk studies.